´ëÇÑ°¡¿Í»ç³¢º´ÇÐȸ Á¦14ȸ °¡¿Í»ç³¢º´ ½ÉÆ÷Áö¿ò : 2019-06-01±³À°ÀÏÀÚ : 2019-06-01
±³À°Àå¼Ò : °¡Åç·¢´ëÇб³ ¼ºÀDZ³Á¤ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£
±³À°ÁÖÁ¦ :
Á¦14ȸ °¡¿Í»ç³¢º´ ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇѼҾưúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ°¡¿Í»ç³¢º´ÇÐȸ
´ã´çÀÚ : ±è¼ºÇý
¿¬¶ôó : 02-3779-1206
À̸ÞÀÏ :
rohetkim@yahoo.co.kr ±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í Àü¹®ÀÇ / Àü°øÀÇ,ÀÇ·á±â»ç,°£È£»ç / Çлý ´çÀϵî·Ïºñ: 70,000 / 30,000 / ¹«·á »çÀüµî·Ïºñ: 60,000 / 20,000 / ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 09:00~09:15 The results of 2015-17 Nationwide survey of Kawasaki disease in Korea ±è±â¹ü(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 09:15~09:30 Genetics: the role of B cell immunity in Kawasaki disease ÀÌÁ¾±Ø(¾Æ»ê»ý¸í°úÇבּ¸¼Ò)
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 09:30~09:45 A review of recent microRNA researches of Kawasaki disease À±½Å¿ø(Á߾Ӵ뺴¿ø)
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 09:45~10:00 Epigenetics on Kawasaki disease Á¤´ëö(¼¿ï¼º¸ðº´¿ø)
Åä·Ð 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 10:00~10:15 ÁöÁ¤Åä·Ð ½ÅÀºÁ¤,À±°æ¸²,À̼ö¿µ,ÀüÇö¿Á(ÀÎÇϴ뺴¿ø,°µ¿°æÈñ´ëº´¿ø,ºÎõ¼º¸ðº´¿ø,°¸ª¾Æ»êº´¿ø)
ÈÞ½Ä 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 10:15~10:40 Coffee break ()
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 10:40~11:30 ±¸¿¬ ¹ßÇ¥ ±è¼ºÈ£,ÀÌÇØ¿ë(ºÎõ¼¼Á¾º´¿ø,¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø)
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 11:30~12:00 ¡°°¡¿Í»ç³¢º´°ú ÇÔ²² ÇÑ 40³â¡± ÀÌ°æÀÏ(°¡Å縯´ëÇб³ ´ëÀü¼º¸ðº´¿ø)
½Ä»ç 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 12:00~13:00 Á¡½É ½Ä»ç ()
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 13:00~13:10 Characteristics of Kawasaki disease manifested by abdominal symptoms À±ÀÚ°æ(ºÎõ¼¼Á¾º´¿ø)
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 13:10~13:20 Kawasaki disease with lymphadenopathy first presentation ¼ÕÀ缺(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 13:20~13:30 Vital signs as predictor of IVIG resistance in children with Kawasaki disease õÀºÁ¤(°Ç¾ç´ëº´¿ø)
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 13:30~13:40 Is Harada score still the best predictor of coronary artery aneurysm? Çϱâ¼ö(°í´ë±¸·Îº´¿ø)
Åä·Ð 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 13:40~14:00 ÁöÁ¤Åä·Ð °íÈÆ,°ûÁöÈñ,±è¼ºÈÆ,ÃÖÈñÁ¤(ºÎ»ê´ëº´¿ø,°ºÏ»ï¼ºº´¿ø,â¿ø»ï¼ºº´¿ø,°è¸í´ëµ¿»êÀÇ·á¿ø)
ÈÞ½Ä 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 14:00~14:20 Coffee break ()
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 14:20~15:10 Áõ·Ê ¹ßÇ¥ ±æÈ«·®,±è¿ë¿í(Ãæ³²´ëº´¿ø,±¤Áֱ⵶º´¿ø)
ÈÞ½Ä 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 15:10~15:30 Coffee break ()
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 15:30~15:40 Italian guidelines and European recommendations of management of patients with Kawasaki disease ±è¼ºÇý(ÇѸ²´ë¼º½Éº´¿ø)
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 15:40~15:50 Echocardiographic functional studies during the acute phase of Kawasaki disease °¼öÁ¤(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 16:00~16:10 Clinical usefulness of NT-proBNP/BNP and Procalcitonin Çѹ̿µ(°æÈñ´ëº´¿ø)
±³À°½Ã°£ 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 16:10~16:20 Use of new drugs – statins, Anakinra, others (ARB, doxycycline, etc) Á¤¼öÀÎ(¾ÆÁִ뺴¿ø)
Åä·Ð 06-01 ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 1003È£ 16:20~16:30 ÁöÁ¤Åä·Ð ¾È°æÁø,À±ÁöÈ«,À̼±Çâ,Á¤¼¼¿ë(±æº´¿ø,¼¿ï¼º¸ðº´¿ø,¼øõÇâ´ëºÎõº´¿ø,½ÅÃ̼¼ºê¶õ½ºº´¿ø)